8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Oct 26, 2010)

Filed October 26, 2010For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) filed an 8-K on October 26, 2010, to announce its financial results for the third quarter ended September 30, 2010. The report primarily references a press release (Exhibit 99) containing detailed operational and financial data. Investors should review this press release for specific earnings per share, revenue figures, and any management commentary on performance drivers and future outlook. While the 8-K itself does not contain the financial details, it serves as the official notification of the release of this information. The furnished press release is the crucial document for understanding Biogen Idec's performance during the period, including trends in key product sales and the company's overall financial condition.

Key Highlights

  • 1Biogen Idec reported its third-quarter 2010 financial and operational results on October 26, 2010.
  • 2The 8-K filing incorporates by reference a press release (Exhibit 99) containing the detailed results.
  • 3Investors need to consult the furnished press release for specific financial figures and performance metrics.
  • 4The filing is made under Item 2.02 (Results of Operations and Financial Condition).
  • 5The press release is furnished and not deemed 'filed' under Section 18 of the Exchange Act, limiting its legal liability scope.
  • 6The filing also includes an Exhibit Index, confirming the press release is the primary accompanying document.

Frequently Asked Questions

The specific financial results for the three months ended September 30, 2010, are contained within the press release issued by Biogen Idec on October 26, 2010, which is furnished as Exhibit 99 to this 8-K filing.

This 8-K filing itself does not detail the key financial metrics. It serves to announce that Biogen Idec has released its results in an accompanying press release (Exhibit 99), which would contain information such as revenue, earnings per share, and other operational data.

When a document is 'furnished' under Item 2.02, it means it is being provided to the SEC for informational purposes but is not subject to the liabilities and legal scrutiny associated with documents formally 'filed' under Section 18 of the Securities Exchange Act of 1934 or incorporated into registration statements.

The 8-K filing was signed by Robert A. Licht, Senior Vice President, on behalf of Biogen Idec Inc.